乳腺导管原位癌放疗加量后的晚期毒性与生活质量:BONBIS随机试验
BONBIS多中心随机III期试验纳入2004例完整切除的导管原位癌患者,术后全乳放疗后随机加或不加16 Gy瘤床加量。中位随访66.9个月,加量组≥2级乳腺皮下纤维化发生率为7.0%,显著高于不加量组的2.8%(P<.001),且加量组长期乳腺症状更明显。
要点
- 全乳放疗加16 Gy瘤床加量显著增加≥2级乳腺皮下纤维化(7.0% vs 2.8%,P<.001)。
- 加量组长期乳腺症状评分更差(组别×时间交互P=.001),身体意象首次恶化风险升高(HR=1.19)。
- 乳腺临床靶体积≥500 cm³与≥2级乳腺皮下纤维化相关(OR=1.6)。
核心结论
- 瘤床加量显著增加≥2级乳腺皮下纤维化发生率和持续性乳腺症状。
- 加量组身体意象首次恶化风险显著升高(HR=1.19;95%CI,1.00-1.41)。
研究设计与样本
- 共2004例完整切除的导管原位癌患者,术后全乳放疗后随机加或不加16 Gy瘤床加量。
- 本文报告晚期毒性、健康相关生活质量及乳腺皮下纤维化预测因素等次要终点,主要终点尚未达到。
主要发现
- 中位随访66.9个月(95%CI,65.1-67.8),≥2级乳腺皮下纤维化总体发生率为4.9%。
- ≥2级乳腺皮下纤维化在加量组为7.0%,不加量组为2.8%(P<.001)。
- ≥2级急性和晚期毒性呈正相关(P=.005)。
- ≥2级乳腺皮下纤维化与加量相关(OR=2.6;95%CI,1.62-4.30),与乳腺临床靶体积≥500 cm³相关(OR=1.6;95%CI,1.01-2.51)。
- QLQ-C30和QLQ-BR23各领域及症状评分中,仅乳腺症状评分存在组别×时间交互效应(P=.001),加量组长期乳腺症状更明显。
关键数值与推荐
- 晚期放疗毒性采用美国国家癌症研究所不良事件通用术语标准v3.0分级。
- 生活质量采用EORTC QLQ-C30 v3.0和QLQ-BR23评估。
- 瘤床加量剂量为16 Gy。
临床怎么用
- 对导管原位癌患者考虑瘤床加量时,应权衡≥2级乳腺皮下纤维化和持续乳腺症状风险。
- 乳腺临床靶体积≥500 cm³者加量后乳腺皮下纤维化风险更高,决策时需关注。
局限性
- 主要终点尚未达到,本文仅报告次要终点。
- 中位随访66.9个月,晚期毒性可能尚未完全显现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In ductal carcinoma in situ, whole breast radiation therapy (WBRT) reduces local recurrence rates, but ipsilateral breast events at 10 years were observed in 15% to 19% of 50-year-old patients. The BONBIS trial (NCT00907868) assessed the effect of an additional localized radiation boost on local recurrence-free survival (primary endpoint). METHODS AND MATERIALS: This large multicenter (n = 53), randomized, open-label phase 3 trial was conducted from November 2008 to July 2014. In total, 2004 patients with complete ductal carcinoma in situ resection underwent postsurgery WBRT followed or not by a 16-Gy boost in the tumor bed. Only late radiation therapy-induced toxicity occurrence (National Cancer Institute Common Terminology Criteria for Adverse Events v3.0), health-related quality of life European Organisation for Research and Treatment Of Cancer (EORTC) Quality of life Cancer Patients (QLQ-C30) v3.0 and EORTC Quality of life Breast Cancer Patients (QLQ-BR23), and potential predictive factors of breast subcutaneous fibrosis (BSCF) (ie, secondary endpoints) will be reported here because the primary endpoint has not been reached yet. RESULTS: After a median follow-up of 66.9 months (95% CI, 65.1-67.8), grade ≥2 BSCF was observed in 4.9% of patients (7.0% in the WBRT + boost vs 2.8% in the WBRT arm; P < .001). Grade ≥2 acute and late toxicities were positively correlated (P = .005). Grade ≥2 BSCF was correlated with the boost (odds ratio = 2.6; 95% CI, 1.62-4.30) and breast clinical target volume ≥500 cm3 (odds ratio = 1.6; 95% CI, 1.01-2.51). Among the QLQ-C30 and QLQ-BR23 domain and symptom scores, only the breast symptom scores exhibited an arm-by-time interaction effect (P = .001) with a greater long-term breast symptom experience in the WBRT + boost arm. Time to first deterioration analysis showed a statically significant deterioration for body image in the WBRT + boost arm (hazard ratio = 1.19; 95% CI, 1.00-1.41). CONCLUSIONS: The boost significantly increased grade ≥2 BSCF occurrence and persistent breast symptoms.
引用
- Bourgier C, Mollevi C, Cowen D, et al. Late Toxicities and Quality of Life After a Radiation Boost for Breast Ductal Carcinoma In Situ: Boost or No Boost in DCIS Randomized Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 40752655. doi:10.1016/j.ijrobp.2025.07.1442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。